

Bankura Sammilani Medical College

Phase II class routine

	9-10am	10-11am	11-1.30 Clinical posting	1.30- 2.30 pm reces s	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L1 IM1.1 heart diseases RHD,CAD	L1 CM7.1 Epidemiolog y concept			P1 PA23.1 Urine examinati on A	P1 PH1.3 Drug formulation, delivery B	P1 MI1.1 Microscopy C
Tues	L1 MI1.1 Introductio n, history	L1 PH1.1, 1.9 Drug nomenclatur e			C	A	B
Wed	L1 PA1.1,1.2,1 .3 History common diseases	L2 PH1.2,1.3 EBM, TDM, Drug formulations			B	C	A
Thurs	L1 SU1.1 response to injury	L2 PA2.1,2.2 Cell injury			P2 PA23.1 A	P2 PH1.3 B	P2 MI1.2 C
Fri	AETCOM	L2 MI1.1 Bacteria morphology			C	A	B
Sat	L3 PH1.11 Drug administrat ion	L3 PA2.4,2.7 Cell death, apoptosis			B	C	A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30 pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM

Mon	L2 IM1.1 heart diseases RHD,CAD	L3 MI1.1 Bacterial genetics			P3 PA23.2 Body fluid A	P3 PH1.9 Nomencla ture B	P3 MI1.1 Taxonomy SGD C
Tues	L4 MI1.6 Antimicrobial resistance	L4 PH1.42,1.43 Chemotherapy principles			C	A	B
Wed	L4 PA2.3,2.5 Gangrene, calcification	L5 PH1.42,1.43 Chemotherapy principles			B	C	A
Thurs	L2 SU1.2,1.3 response to injury	L5 PA2.6 Cellular adaptation			P4 PA23.3 Semen analysis , TFT A	P4 PH1.10 Prescripti on rationality B	P4 MI1.1 Bacteria morphology C
Fri	Holiday						
Sat	Holiday						

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L3 IM1.3 RHD Infective Endocarditis	L2 CM7.5 Descriptive statistics			P5 PA23.3 Cytology, staining A	P5 PH1.10 Prescription criticism B	P5 MI8.9,8.10 Specimen collection Transport C
Tues	L5 MI1.1 bacterial infection	L6 PH1.10 Prescription writing			P4 PA23.3 Semen analysis, TFT C	P4 PH1.10 Prescription rationality A	P4 MI1.1 Bacteria morphology B
Wed	L6 PA3.1 Amyloidosis	L7 PH1.4 Absorbtion, distribution			P4 PA23.3 Semen analysis, TFT B	P4 PH1.10 Prescription rationality C	P4 MI1.1 Bacteria morphology A
Thurs	L3 SU3.1 blood components	L7 PA4.1,4.2 Acute inflammation			P6 PA23.3 LFT A	P6 PH1.11 Routes drug administration B	P6 MI1.2 Staining technique C
Fri	AETCOM	MI1.1 Overview bact infectn			P5 PA23.3 Cytology, staining C	P5 PH1.10 Prescription criticism A	P5 MI8.9,8.10 Specimen collection Transport B
Sat	L8 PH1.4 Metabolism, excretion	L8 PA 4.3 chronic Inflammation			P5 PA23.3 Cytology, staining B	P5 PH1.10 Prescription criticism C	P5 MI8.9,8.10 Specimen collection Transport A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L4 IM1.4,1.5 1.6 HF	L7 MI1.1 virology			P7 PA2.8 Cell injury A	P7 PH2.1 Dosage forms B	P7 MI1.2 Gram staining C
Tues	L8 MI1.1 parasitology	L9 PH1.5 Drug action			P6 PA23.3 LFT C	P6 PH1.11 Routes drug administration A	P6 MI1.2 Staining technique B
Wed	Holiday						
Thurs	L4 SU3.2,3.3 blood components	L9 PA5.1 Repair & regeneraion			P8 PA3.2 Amyloidosis A	P8 PH2.2 ORS B	P8 MI1.1 Culture media(SGD) C
Fri	L1 FM1.1,1.2 history introduction	L9 MI1.1 mycology			P7 PA2.8 Cell injury C	P7 PH2.1 Dosage forms A	P7 MI1.2 Gram staining B
Sat	L10 PH1.5 DRUG ACTION	L10 PA6.1,6.2 Oedema, congestion			P6 PA23.3 LFT B	P6 PH1.11 Routes drug administration C	P6 MI1.2 Staining technique A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L5 IM1.7,1.8 Arrhythmia in HF	L3 CM7.5 Case control study			P9 PA4.4 Acute inflammation A	P9 PH1.6,1.7 ADR Pvigilance B	P9 MI1.6,1.1 Lab diag bacterial inf(SGD) C
Tues	L10 MI1.3 Epidemiology infectious dis	L11 PH1.7 ADR			P8 PA3.2 Amyloidosis C	P8 PH2.2 ORS A	P8 MI1.1 Culture media(SGD) B
Wed	L11 PA6.3 Shock	L12 PH1.6 ADR reporting Pvigilance			P7 PA2.8 Cell injury B	P7 PH2.1 Dosage forms C	P7 MI1.2 Gram staining A
Thurs	L5 SU2.1 shock	L12 PA6.4 thrombosis			P10 PA4.4 Chronic inflammation A	P10 PH1.6,1.7 ADR B	P10 MI1.1 Bacterial inf. Patho C (SGD)
Fri	AETCOM	L11 MI1.1 Inert acquired immunity			P9 PA4.4 Acute inflammation C	P9 PH1.6,1.7 ADR Pvigilance A	P9 MI1.6,1.1 Lab diag bacterial inf(SGD) B
Sat	L13 PH1.8 drug interaction	L13 PA6.5,6.6 embolism, ischaemia			P8 PA3.2 Amyloidosis B	P8 PH2.2 ORS C	P8 MI1.1 Culture media(SGD) A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L6 IM1.9 Acute rheumatic fever	L12 MI1.8 antibody			P11 PA6.7 infarction	P11 PH3.4 ADR reporting	P11 MI1.1 Viral lab diag
Tues	L13 MI1.8 Ag- Ab reaction	L14 PH1.12, 1.56 dose calculation			P10 PA4.4 Chronic inflammation	P10 PH1.6,1.7 ADR	P10 MI1.1 Bacterial inf. Patho (SGD)
Wed	L14 PA7.1,7.2 neoplasia	L15 PH1.14 Cholinergic drugs			P9 PA4.4 Acute inflammation	P9 PH1.6,1.7 ADR Pvigilance	P9 MI1.6,1.1 Lab diag bacterial inf(SGD)
Thurs	L6 SU2.2,2.3 shock	L15 PA7.3 carcinogens			P12 PA8.3 diagnostic cytology	P12 PH2.4 Dose calculation	P12 MI1.2 Stool microscopy
Fri	L2 FM1.3 I.P.C,inquest Cr.P.C	L14 MI1.8 Ag- Ab reaction			P11 PA6.7 infarction	P11 PH3.4 ADR reporting	P11 MI1.1 Viral lab diag
Sat	L16 PH1.14 anticholinergic	L16 PH7.4,7.5 Tumour immunology			P10 PA4.4 Chronic inflammation	P10 PH1.6,1.7 ADR	P10 MI1.1 Bacterial inf. Patho (SGD)

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L7 IM1.21 Ac & Subacute (Bac) endo carditis	L4 CM7.5 Cohort study			P13 PA8.3 Cytology A	P13 PH1.12 dose calculation B	P13 MI1.1,1.2 fungal lab diag C
Tues	L15 MI1.8 complement	L17 PH1.14 adrenergic drug			P12 PA8.3 diagnostic cytology C	P12 PH2.4 Dose calculation A	P12 MI1.2 Stool microscopy B
Wed	L17 PA8.1,8.2 cytology	L18 PH1.14 antiadrenergic drug			P11 PA6.7 Infarction B	P11 PH3.4 ADR reporting C	P11 MI1.1 Viral lab diag A
Thurs	L7 SU4.1,4.2 Burn	L18 PA9.1,9.2 immunity hypersensitivity			P14 PA13.2 Anticoagulants A	P14 PH2.3 i.v setting B	P14 MI1.1 Normal human flora (SGD) C
Fri	AETCOM	L16 MI1.8 components of immune system			P13 PA8.3 Cytology C	P13 PH1.12 dose calculation A	P13 MI1.1,1.2 fungal lab diag B
Sat	L19 PH1.14 sk muscle relaxant	L19 PH9.4,9.5,9.7 autoimmunity disorders			P12 PA8.3 diagnostic cytology B	P12 PH2.4 Dose calculation C	P12 MI1.2 Stool microscopy A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L8 IM4.1,2,3 host immune status, febrile response	L17 MI1.8 immune system components			P15 PA13.2 anticoagulant	P15 PH1.8 drug interaction	P15 MI1.8,8.15 Ag-Ab reaction
Tues	L18 MI1.8 immune response	L20 PH1.17 local anaesthesia			P14 PA13.2 anticoagulants	P14 PH2.3 i.v setting	P14 MI1.1 Normal human flora (SGD)
Wed	L20 PA9.3 HLA	L21 PH1.18 General anaesthesia			P13 PA8.3 cytology	P13 PH1.12 dose calculation	P13 MI1.1,1.2 fungal lab diag
Thurs	L8 SU4.3,4.4 Burn	L21 PA9.6 HIV/AIDS			P16 PA13.5 PBS Anaemia	P16 PH1.8 Drug interaction	P16 MI1.2 Acid fast staining
Fri	L3 FM1.4,1.5 summons, witness, courts	L19 MI1.8 immune response			P15 PA13.2 anticoagulant	P15 PH1.8 drug interaction	P15 MI1.8,8.15 Ag-Ab reaction
Sat	L22 PH1.16 antihistaminics	L22 PA10.4 Common infections			P14 PA13.2 anticoagulants	P14 PH2.3 i.v setting	P14 MI1.1 Normal human flora (SGD)

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L9 IM1.24,1.25 drugs for HF surgical intervention	CM7.5 experimental study			P17 PA13.5 PBS Anaemia A	P17 PH1.8 drug interaction B	P17 MI1.8 Acid fast staining C
Tues	L20 MI2.7 HIV/AIDS	L23 PH1.16 5HT related drugs			P16 PA13.5 PBSAnaemia C	P16 PH1.8 Drug interaction A	P16 MI1.2 Acid fast staining B
Wed	L23 PA10.1,2.3 malaria, leprosy, cysticercosis	L24 PH1.16 NSAIDS			P15 PA13.2 Anticoagulant B	P15 PH1.8 drug interaction C	P15 MI1.8,8.15 Ag-Ab reaction A
Thurs	L9 SU5.1,5.2 Wound Healing & care	L24 PA11.1,11.2 genetic disorders of childhood			P18 PA14.3 PBS microcytic A	P18 PH1.8 drug interaction B	P18 MI1.2 stool microscopy C
Fri	AETCOM	L21 MI 2.7 HIV/AIDS			P17 PA13.5 PBS Anaemia C	P17 PH1.8 drug interaction A	P17 MI1.8 Acid fast staining B
Sat	L25 PH1.48 HIV/UTI/STD	L25 PA11.3 storage disorder			P16 PA13.5 PBS Anaemia B	P16 PH1.8 Drug interaction	P16 MI1.2 Acid fast staining

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30 pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L10 IM2.1,2 ischaemic heart dis	L22 MI1.1 Hyper sensitivity			P19 PBS haemolytic anaemia A	P19 PH1.8 Drug interaction B	P19 MI8.5,8.6,87 healthcare asso inf (sgd) C
Tues	L23 MI1.10 autoimmune	L26 PH1.16 migraine			P18 PA14.3 PBS microcytic anaemia C	P18 PH1.8 drug interaction A	P18 MI1.2 stool microscopy B
Wed	L26 PA12.1,12.2 12.3 PEM, obesity, pollution	L27 PH1.19 sedative anxiolytic			P17 PA13.5 PBS Anaemia B	P17 PH1.8 drug interaction C	P17 MI1.8 Acid fast staining A
Thurs	L10 SU6.1,6.2 surgical infections	L27 PA13.1,13.3, 13.4 hematopoeisi s			P20 PA16.7 cross matching A	P20 PH3.1 Prescriptio n writing B	P20 MI8.7 hand hygeine, ppe C
Fri	L4 FM1.6,7,8 perjury dying declaration	L24 MI1.10 immune disorders			P19 PBS haemolytic anaemia C	P19 PH1.8 Drug interaction A	P19 MI8.5,8.6,87 healthcare asso inf (sgd) B
Sat	L28 PH1.19 antipsychoti c	L28 PA14.1,14.2 microcytic anaemia			P18 PA14.3 PBS anaemia microcytic B	P18 PH1.8 drug interaction C	P18 MI1.2 stool microscopy A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	Holiday						
Tues	L25 MI1.11 transplant cancer	L29 PH1.16 gout rheumatic			P20 PA16.7 cross matching A	P20 PH3.1 Prescription writing B	P20 MI8.7 hand hygeine, ppe C
Wed	L29 PA15.1,2,3,4 macrocytic anaemia	L30 PH1.19 antidepressants			P19 PBS haemolytic anaemia C	P19 PH1.8 Drug interaction A	P19 MI8.5,8.6,87 healthcare asso inf (sgd) B
Thurs	L11 SU5.1,5.2 Wound Healing & care	L30 PA16.1,16.2 hemolytic anaemia			P21 PA17.2 Bone marrow aspirat A	P21 PH3.1 prescription writing B	P21 MI1.4,1.5 sterilise disinfect C
Fri	A E T C O M	L26 MI1.9 Immuno prophyllaxis			P21 PA17.2 Bone marrow aspirat C	P21 PH3.1 prescription writing A	P21 MI1.4,1.5 sterilise disinfect B
Sat	L31 PH1.19 opioids	L31 PA16.3 thalasaemia sickle cell			P20 PA16.7 cross matching B	P20 PH3.1 Prescription writing C	P20 MI8.7 hand hygeine, ppe A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L11 IM2.3,4 athero sclerosis complicatn	L27 MI2.1,2.2 endocarditis			P22 PA19.3 TB lymph node A	P22 PH3.1 prescription writing B	P22 MI1.5 CSSD visit C
Tues	L28 MI2.1,2,4 blood infection	L32 antimaniac neuro degeneraive			P22 PA19.3 TB lymph node C	P22 PH3.1 prescription writing A	P22 MI1.5 CSSD visit B
Wed	Holiday						
Thurs	L12 SU6.1,6.2 surgical infections	L32 PA16.4,5 PBS hemolytic			P23 PA19.5 hodgkins lymphoma A	P23 PH3.1 prescription writing B	P23 MI8.5,8.6 needle stick injury C
Fri	L5 FM1.9,10 medical evidence MCCD	L29 MI3.3 enteric fever			P23 PA19.5 hodgkins lymphoma C	P23 PH3.1 prescription writing A	P23 MI8.5,8.6 needle stick injury B
Sat	L33 PH1.19 antiepileptic PH1.19	L33 PA17.1 aplastic anaemia			P21 PA17.2 Bone marrow aspirat B	P21 PH3.1 prescription writing C	P21 MI1.4,1.5 sterilise disinfect A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L12 IM2.5 acute coronary syndrome	L6 CM 8.3 National Health Programs			P24 PA19.7 Splenomegaly A	P24 PH3.1 prescription writing B	P24 MI8.7 biomedical wastePPE C
Tues	L30 MI1.1 rickettsial	L34 PH1.20,1.21 ethanol, methanol			P24 PA19.7 Splenomegaly C	P24 PH3.1 prescription writing A	P24 MI8.7 biomedical wastePPE B
Wed	L34 PA18.1 leucopenia cytosis	L35 PH1.22,1.23 drug abuse			P22 PA19.3 TB lymph node B	P22 PH3.1 prescription writing C	P22 MI1.5 CSSD visit A
Thurs	L13 SU7.1,7.2 audit & research	L35 PA18.2 Ac/Chr leukaemia			P25 PA20.1 Plasma cell Myeloma A	P25 PH3.2 Prescriptn Criticism B	P25 MI2.3,8.15 Sepsis,CRBSI C
Fri	AETCOM	L31 MI1.1 haemorrhagic fever viral			P25 PA20.1 Plasma cell Myeloma C	P25 PH3.2 Prescriptn Criticism A	P25 MI2.3,8.15 Sepsis,CRBSI B
Sat	L36 PH1.47 amebiasis antihelminthics	L36 PA19.1,19.2 TB lymphad enopathy			P23 PA19.5 hodgkins lymphoma B	P23 PH3.1 prescription writing C	P23 MI8.5,8.6 needle stick injury A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	PRACTICAL ASSESSMENT (PATHOLOGY)						
Tues 3	PRACTICAL ASSESSMENT (PHARMACOLOGY)						
Wed	PRACTICAL ASSESSMENT (MICROBIOLOGY)						
Thurs	REVISION CLASSES						
Fri	A E T C O M	REVISION CLASSES					
Sat	THEORY ASSESSMENT						

Practical batch division

batch	A	B	C
Roll no	1-67	68-134	134-200

Colour code for subjects

pathology	pharmacology
microbiology	FSM
medicine	surgery
Community medicine	AETCOM

Clinical posting batch division

Batch	A	B	C	D	E	F
Roll no	1-33	34-66	67-99	100-132	133-165	166-200

Clinical posting schedule for Phase II

	medicine	surgery	gynae & obs	paediatrics	community medicine	chest	Derma & Psychiatry
A	1/5 - 31/5	1/6-30/6	1/7-31/7	1/8-31/8	1/9-30/9	1/10-31/10	1/11-31/11
B	1/11-31/11	1/10-31/10	1/5 - 31/5	1/6-30/6	1/7-31/7	1/8-31/8	1/9-30/9
C	1/9-30/9	1/11-31/11	1/10-31/10	1/5 -31/5	1/6-30/6	1/7-31/7	1/8-31/8
D	1/8-31/8	1/9-30/9	1/11-31/11	1/10-31/10	1/5 -31/5	1/6-30/6	1/7-31/7
E	1/7-31/7	1/8-31/8	1/9-30/9	1/11-31/11	1/10-31/10	1/5 -31/5	1/6-30/6
F	1/6-30/6	1/7-31/7	1/8-31/8	1/9-30/9	1/11-31/11	1/10-31/10	1/5 -31/5

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L13 IM2.5 treatment of acute coronary syndrome	L32 MI12.5,8.16 Malaria & Babesiosis			P26 PA22.1 Bl grouping 1 A	P26 PH1.20 alcohol poisoning B	P26 MI1.7,8 Hand Hygiene PPE C
Tues	L33 MI12.5,8.1 6 Malaria & Babesiosis	L36 PH1.24 diuretics			P26 PA22.1 Bl grouping 1 C	P26 PH1.20 alcohol poisoning A	P26 MI1.7,8 Hand Hygiene PPE B
Wed	L36 PA19.4 HI&NHL	L37 PH1.24 diuretics			P24 PA19.7 Splénomegaly B	P24 PH3.1 prescription writing C	P24 MI8.7 biomedical wastePPE A
Thurs	L13 SU7.1,7.2 audit & research	L37 PA19.6 splénomega ly			P27 PA22.2 Bl grouping 2 A	P27 PH1.22 Drug abuse B	P27 MI1.4,5 Sterilization & disinfection C
Fri	L6 FM2.1,2,3, 4 Death- Natural & Unnatural	L34 MI12.5, 8.16 Leishmaniasis & Trypanosomi asis			P27 PA22.2 Bl grouping 2 C	P27 PH1.22 Drug abuse A	P27 MI1.4,5 Sterilization & disinfection B
Sat	L38 PH1.25 Antiplatelet fibrinolytic	L38 PA21.1,2,3 Heamorrhagic disorders			P25 PA20.1 Plasma cell Myeloma B	P25 PH3.2 Prescriptn Criticism C	P25 MI2.3,8.15 Sepsis,CRBSI A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L14 IM2.16,17 thrombolysis, PTCA, CABG in ac coronary syn	L7 CM7.2 Disease transmission prevention control			P28 PA23.1 Urinary examination A	P28 PH3.1 prescription writing B	P28 MI1.5 CSSD visit for sterilization C
Tues	L35 MI2.5,8.16 Lymphatic filariasis	L39 PH1.26 RAAS anticoagulant			P28 PA23.1 Urinary examination C	P28 PH3.1 prescription writing A	P28 MI1.5 CSSD visit for sterilization B
Wed	L39 PA21.4,5 DIC	L40 PH1.25 anticoagulant			P26 PA22.1 Bl grouping 1 B	P26 PH1.20 alcohol poisoning C	P26 MI1.7,8 Hand Hygiene PPE A
Thurs	Holiday						
Fri	AETCOM	L36 MI3.1 GIT infective syndrome			P29 PA23.2 Body fluids C	P29 PH1.23 De- addiction A	P29 MI8.5,6 Needle stick injury B
Sat	L41 PH1.27 antihyperte nsive	L40 PA22.4,5,6,7 Blood banking & transfusion			P27 PA22.2 Bl grouping 2 B	P27 PH1.22 Drug abuse C	P27 MI1.4,5 Sterilization & disinfection A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L15 IM2.18,23 dyslipidaemia	L37 MI3.1 Cholera			P29 PA23.2 Body fluids A	P29 PH1.23 De-addiction B	P29 MI8.5,6 Needle stick injury C
Tues	L38 MI3.1 Cholera	L42 PH1.32,1.33 asthma,COPD			P30 PA23.3 Semen analysis + Thyroid function test C	P30 PH1.13 Cholinergic anticholinergic A	P30 MI8.7 Had hygiene PPE,Biomed waste B
Wed	L41 PA24.1,2 Oralcancers Pepticulcer disease	L43 PH1.32,1.33 asthma,COPD			P28 PA23.1 Urinary examination B	P28 PH3.1 prescription writing C	P28 MI1.5 CSSD visit for sterilization A
Thurs	L1 OG2.1 development genital organs	L42 PA24.4 Carcinoma stomach			P30 PA23.3 Semenanalysis + Thyroid function test A	P30 PH1.13 Cholinergic anticholinergic B	P30 MI8.7 Had hygiene PPE,Biomed waste C
Fri	L7 FM2.5,6,7 FM1.11	L39 MI3.1 amoebiasis			P31 PA23.3 LFT + RFT C	P31 PH1.13 adrenergic antiandre A	P31 MI8.7 Had hygiene PPE,Biomed waste B
Sat	L44 PH1.60 Pharmaco Genomics economics	L43 PA24.5 Tuberculosis of intestine			P29 PA23.2 Body fluids B	P29 PH1.23 De-addiction B	P29 MI8.5,6 Needle stick injury C

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	Holiday						
Tues	L40 MI3.1 helminthiasis	L45 PH1.28 angina			P32 PA24.3 Microscopy- Peptic ulcer C	P32 PH1.32 asthma COPD A	P32 MI8.7 Had hygiene PPE,Biomed waste B
Wed	L44 PA24.6 Inflammatory bowel disease	L46 PH1.28 Angina PVS			P30 PA23.3 Semen analysis + Thyroid function test B	P30 PH1.13 Cholinergic anticholinergic C	P30 MI8.7 Had hygiene PPE,Biomed waste A
Thurs	L2 OG23.1 Normal puberty	L45 PA24.7 Carcinoma of colon			P31 PA23.3 LFT + RFT A	P31 PH1.13 adrenergic antiandrogenic B	P31 MI8.7 Had hygiene PPE,Biomed waste C
Fri	AETCOM	L41 MI3.1 helminthiasis L31			P33 PA25.6 LFT- Interpretation + Viral hepatitis- serology panel C	P33 PH1.33 Antitussive expectorant A	P33 MI2.3,8.15 Sepsis CRBSI, Inf endocarditis B

Sat	L47 PH1.30 Antiarythmic	L46 PA25.1 Bilirubin metabolism, jaundice			P31 PA23.3 LFT + RFT B	P31 PH1.13 adrenergic antiandre C	P31 MI8.7 Had hygiene PPE, Biomed waste A
-----	-------------------------------	---	--	--	---------------------------------	--	---

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L16 IM2.19 Complication of ACS	L42 MI3.7 Inf syn hepatobiliary			P32 PA24.3 Microscopy- Peptic ulcer A	P32 PH1.32 asthma COPD B	P32 MI8.2 Hand hygiene BMW, PPE C
Tues	L43 MI4.1,2,3 inf syn skin, soft tissue	L48 PH1.29 Congestive HF			P34 PA25.6 Obstructive vs non-obstructive jaundice C	P34 PH3.3 Drug promotional lit review A	P34 MI8.1 Brucellosis leptospira B
Wed	L47 PA25.2 Hepatic failure	L49 PH1.29 Congestive HF			P32 PA24.3 Microscopy- Peptic ulcer B	P32 PH1.32 asthma COPD C	P32 MI8.2 hand hygiene BMW, PPE A
Thurs	L3 OG23.3 Anormal puberty	L48 PA25.3 Viral Hepatitis			P33, PA25.6 LFT- Interpretation + Viral hepatitis-serology panel A	P33 PH1.33 Antitussive expectoran B	P33 MI2.3,8.15 Sepsis CRBSI C

Fri	L8 FM2.8 Signs of death	L44 MI4.3 viral exanthema			P35 PA27.8 Interpretation-Acute coronary syndrome C	P35 PH1.34 GERD, Acid peptic disorder antiemetic A	P35 MI3.4,8.14 Enteric fever Scrub typhus B
Sat	L50 PH1.31 dyslipidaemia	L49 PA25.4 Alcoholic liver disease & Cirrhosis			P33 PA25.6 LFT- Interpretation + Viral hepatitis-serology panel B	P33 PH1.33 Antitussive expectorant C	P33 MI2.3,8.15 Sepsis CRBSI A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L17 IM2.20 Pathogenesis management of ACS	L8 CM7.3,7.4 Morbidity Mortality epidemiology			P34, PA25.6 Obstructive vs non- obstructive jaundice A	P34 PH3.3 Drug prom tional lit review B	P34 MI8.1 Brucellosis leptospira C
Tues	L45 MI4.3 viral cutaneous lesion	L51 PH1.34 antidiarrhoeal Antiulcer			P36 PA31.3 Ca Breast- morphology & microscopy C	P36 PH1.34 GERD, Acid peptic dis antiemetic A	P36 MI1.2 Gram staining B
Wed	L50 PA25.5 Portal hypertensi on	L52 PH1.34 antiemetic			P34 PA25.6 Obstructive vs non- obstructive jaundice B	P34 PH3.3 Drug prom tional lit review C	P34 MI8.1 Brucellosis leptospira A
Thurs	L4 OG3.1 Menstruati on	L51 PA26.1 Pneumonia			P35 PA27.8 Interpretatio n-Acute coronary syndrome A	P35 PH1.34 GERD, Acid peptic dis antiemetic B	P35 MI3.4,8.14 Enteric feve Scrub typhu C
Fri	AETCOM	L46 MI6.1 Resp tract inf			P37 PA34.4 Tumors of skin C	P37 PH3.5 P DRUG A	P37 MI2.7,8.15 HIV Dengue B

Sat	L53 PH1.34 IBD, laxative	L52 PA26.2 Lung abscess			P35 PA27.8 Interpretation-Acute coronary syndrome B	P35 PH1.34 GERD, Acid peptic, anti emeti C	P35 MI3.4,8.14 Enteric feve Scrub typhu A
-----	-----------------------------------	-------------------------------	--	--	--	--	---

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L18 IM3.1.2 Pneumonia microbiology	L47 MI6.1 Bact lobar pneumonia			P36 PA31.3 Ca Breast- morphology & microscopy A	P36 PH1.34 GERD, Acid peptic dis antiemetic B	P36 MI1.2 Gram staining C
Tues	L48 MI6.1,8.16 TB NTM	L54 PH1.44 Anti TB			P38 PA35.3 CSF interpretation C	P38 PH3.5 P DRUG A	P38 MI1.2 Acid fast Stain B
Wed	L53 PA26.3 Obstructive airway ds & bronchiect asis	L55 PH1.45 XDR, MDR TB			P36 PA31.3 Ca Breast- morphology & microscopy B	P36 PH1.34 GERD, Acid peptic dis antiemetic C	P36 MI1.2 Gram staining A
Thurs	L5 OG24.1 Abnormal menstruation	L54 PA26.4 Tuberculosis			P37 PA34.4 Tumors of skin A	P37 PH3.5 P DRUG B	P37 MI2.7,8.15 HIV Dengue C

Fri	L9 FM2.8 Rigor mortis	L49 MI6.1 myxovirus			P39 PA25.6 LFT- Interpretatio n + Viral hepatitis- serology panel C	P39 PH3.7 EML A	P39 MI2.6,8.15 Malaria filaria B
Sat	L56 PH1.36 Thyroid hormones	L55 PA26.5 Occupational lung ds			P37 PA34.4 Tumors of skin B	P37 PH3.5 P DRUG A	P37 MI2.7,8.15 HIV Dengue C

	9-10am	10-11am	11- 1.30 Clinical posting	1.30- 2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L19 IM3.3 Pneumonia pathogenes is	L9 CM6.1 research question			P38 PA35.3,CSF interpretatio n A	P38 PH3.5 P DRUG B	P38 MI1.2 Acid fast Stain C
Tues	L50 MI6.1 COVID 19 Corona inf	L57 PH1.36 Diabetes mellitus			P40 PA23.3 LFT + RFT C	P40 PH4.1 Drug administer mannequin A	P40 MI1.1h Sys mycosis B
Wed	L56 PA26.6 Tumors of lung & pluera	L58 PH1.36 Diabetes mellitus			P38 PA35.3 CSF interpretatio n B	P38 PH3.5 P DRUG C	P38 MI1.2 Acid fast Stain A

Thurs	L6 OG23.1 Puberty menorrhagia	L57 PA26.7 Mesotheliom a			P39 PA25.6 LFT- Interpretatio n + Viral hepatitis- serology panel A	P39 PH3.7 EML B	P39 MI2.6,8.15 Malaria filaria C
Fri	AETCOM	L51 MI5.1,2 Infective syn CNS			P41 PA27.8 Interpretatio n-Acute coronary syndrome C	P41 PH4.1 Drug administer mannequin A	P41 MI3.5 food poisoning B
Sat 2/10/21							

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L20 IM3.16,17 Pneumonia supportive therapy	L52 MI5.1 Bacterial meningitis			P40 PA23.3 LFT + RFT A	P40 PH4.1 Drug administer mannequin B	P40 MI1.1h Sys mycosis C
Tues	L53 MI4.1 Tetanus	L59 PH1.38 cortico steroids			P42 PA25.6 Obstructive vs non- obstructive jaundice C	P42 PH4.1 Drug administer mannequin A	P42 MI3.2 Dysentery diarrhoea B
Wed	Holiday						
Thurs	L7 OG27.1 PID	L58 PA27.1 Arteriosclero sis vs Atheroscleros i			P41 PA27.8 Interpretatio n-Acute coronary syndrome A	P41 PH4.1 Drug administer mannequin B	P41 MI3.5 food poisoning C
Fri	L10 FM2.9.10 Putrifaction ,time since death	L54 MI5.2 Viral encephalitis encepalopath			P43 PA23.3 Semenanalsi s + Thyroid function test C	P43 PH4.2 CAL A	P43 MI1.2 Gram stain B
Sat	L60 PH1.36 Ca metabo lism	L59 PA27.2 Aneurysms			P39 PA25.6 LFT- Interpretatio n + Viral hepatitis-	P39 PH3.7 EML C	P39 MI2.6,8.15 Malaria filarial A

					serology panel B		
	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	Holiday						
Tues	Holiday						
Wed	Holiday						
Thurs	Holiday						
Fri	Holiday						
Sat	L61 PH1.371.41 ant pitutary hormone	L60 PA27.3 Heart Failure			P40 PA23.3 LFT + RFT B	P40 PH4.1 Drug administer mannequin C	P40 MI1.1h Sys mycosis A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	Holiday						
Tues	Holiday						
Wed	Holiday						
Thurs	Holiday						
Fri	Holiday						
Sat	L62 PH1.53 Poisoning chelating	L61 PA27.4 Rheumatic fever			P41 PA27.8 Interpretatio n-Acute coronary syndrome B	P41 PH4.1 Drug administer mannequin C	P41 MI3.5 food poisoning A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L21 IM3.15,17 Ventilation, hospitalization in pneumonia	L10 CM6.2 Statistical data			P42 PA25.6 Obstructive vs non- obstructive jaundice A	P42 PH4.1 Drug administer mannequin B	P42 MI3.2 Dysentery diarrhoea C
Tues	L56 MI7.1,2 Inf syn genital tract	L63 PH1.39 Contracep tion drugs			P44 PA 22.1,2 Blood grp PA16.7 cross matching C	P44 PH4.2 CAL A	P44 MI3.1,6 Misc B
Wed	L62 PA27.5 Ischemic heart disease	L64 PH1.39 Contracep tion drugs			P42 PA25.6 Obstructive vs non- obstructive jaundice B	P42 PH4.1 Drug administer mannequin C	P42 MI3.2 Dysentery diarrhoea A

Thurs	L8 OG21.1 Contraception, IU Device	L63 PA27.6 Infective endocarditis			P43 PA23.3 Semenanalysis + Thyroid function test A	P43 PH4.2 CAL B	P43 MI1.2 Gram stain C
Fri	AETCOM	L57 MI8.5,6 healthcare asso infection			P45 PA19.5 hodgkins lymphoma C	P45 PH4.2 CAL A	P45 MI3.1 Int protozoal Inf B
Sat	L65 Ph1.40 Infertility Erectile dys	L64 PA27.7 Pericarditis & Pericardial effusion			P43 PA23.3 Semenanalysis + Thyroid function test B	P43 PH4.2 CAL C	P43 MI1.2 Gram stain A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L22 IM3.19 pneumococcal and influenza vaccine	L58 MI1.6 Antimicrobial steward			P44 PA 22.1,2 Blood grp PA16.7 cross matching A	P44 PH4.2 CAL B	P44 MI3.1,6 Misc C
Tues	L59 MI8.3 oncogenic organism	L66 PH1.1 Gout, anti rheumatic			P46 PA20.1 Plasma cell Myeloma C	P46 PH2.3 IV drip setting A	P46 MI1.2, 3.2 Stool micro protozoal B
Wed	L65 PA27.9 Cardiomyo pathies	L67 PH1.35 anaemia			P44 PA 22.1,2 Blood grp PA16.7 cross matching B	P44 PH4.2 CAL C	P44 MI3.1,6 Misc A
Thurs 4/11/21	Holiday						
Fri 5/11/21	Holiday						
Sat 6/11/21	Holiday						

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L23 IM1.21 acute subacute endocarditis	L11 CM6.3 Frequency distribution			P45 PA19.5 hodgkins lymphoma A	P45 PH4.2 CAL B	P45 MI3.1 Int protozoal Inf C
Tues	L60 MI7.2 Gonococcal NGO	L68 PH1.35 Anaemia, CSF			P47 PA23.1 Urinary examination C	P47 PH3.8 Communica te proper drug use A	P47 MI3.1 int helminth inf B
Wed	L66 PA27.10 Syphillis and the CVS	L69 PH1.46 Antileprotic			P45 PA19.5 hodgkins lymphoma B	P45 PH4.2 CAL C	P45 MI3.1 Int protozoal Inf A
Thurs	L9 OG21.1 Oral contracepti on	L67 PA28.1 Histology of kidney			P46 PA20.1 Plasma cell Myeloma A	P46 PH2.3 IV drip setting B	P46 MI1.2, 3.2 Stool micro protozoal C
Fri	AETCOM	L61 MI UTI lab diagnosis			P48 PA24.3 Microscopy- Peptic ulcer C	P48 PH5.1 Ethics on drug use A	P48 MI1.2 Acid fast staining B
Sat	L70 PH1.49 anticancer	L68 PA28.2 Clinical syndromes of kidney			P46 PA20.1 Plasma cell Myeloma B	P46 PH2.3 IV drip setting C	P46 MI1.2, 3.2 Stool micro protozoal A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	Holiday						
Tues	L62 MI 7.1,2 STI Lab diagnosis	L71 PH1.49 anticancer			P49 PA31.3 Ca Breast- morphology & microscopy C	P49 PH5.2 Communica te Drug therapy, device storage A	P47 MI3.1 int helminth inf B
Wed	L69 PA28.3 Acute renal failure	L72 PH1.50 organ transplant Reject manag Immuno Modulator			P47 PA23.1 Urinary examination B	P47, PH3.8 Communica te proper drug use C	P49 MI1.2,3.2 stool micro cystode nematode A
Thurs	L10 OG20.1 MTP	L70 PA28.4 Chronic renal failure			P47 PA23.1 Urinary examination A	P47, PH3.8 Communica te proper drug use B	P47 MI3.1 int helminth inf C
Fri	Holiday						
Sat	L73 PH1.54 vaccines	L71 PA28.5 Glomerular diseases			P48 PA24.3 Microscopy- Peptic ulcer B	P48 PH5.1 Ethics on drug use C	P48 MI1.2 Acid fast staining A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	SDL	L12 CM 6.3 Measures of central tendency and dispersion			P48 PA24.3 Microscopy- Peptic ulcer A	P48 PH5.1 Ethics on drug use B	P48 MI1.2 Acid fast staining C
Tues	L63 MI 8.8 Air, water surface bacteriolog	L74 PH1.47 malaria			SDL1	P50, PH5.3 Motivate adherence To drug A	P50 MI4.3,4.1,8.15,1.2 strepto staph gram stain B
Wed	L72 PA28.6,7,8 IgA nephropathy	L75 PH1.47 Malaria			P49 PA31.3 Ca Breast-morphology & microscopy B	P49, PH5.2 Communicate Drug therapy, device storage C	P49 MI1.2,3.2 stool microcystode nematode A
Thurs	L11 OG21.1 Tubectomy	L73 PA28.9,10 ATN, pyelonephritis			P49 PA31.3 Ca Breast-morphology & microscopy A	P49, PH5.2 Communicate Drug therapy, device storage B	P49 MI1.2,3.2 stool microcystode nematode C
Fri	AETCOM	L64 MI1.1 Congenital inf			SDL2	P51 PH5.4 Drug Cost compliance A	P51 MI6.2 Throat swan gram stain B
Sat	L76 PH1.55 National Health prog	L74 PA28.11,12,13,15 Vascular ds of kidney,cystic ds, renal stones			SDL3	P50, PH5.3 Motivate adherence To drug C	P50 MI4.3,4.1,8.15,1.2 Strepto,staph gram stain A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	P1,CM 7.5 Epidemiological Descriptive study	L65 MI 8.1 Zoonotic inf			SDL4	P50, PH5.3 Motivate adherence To drug B	P50 MI4.3,4.1,8. 15,1.2 Strepto, staph gram stain C
Tues	L66 MI8.2 Oppurtunistic inf	L77 PH1.57,58 skin and ocular drugs			SDL5	P52, PH5.5 Drug dependenc e manage A	P52 MI6.3 Sputum gram stain B
Wed	L75 PA28.14,16 Tumors of kidney	L78 PH1.59 OTC FDC, EML, herbal			SDL6	P51 PH5.4 Drug Cost compliance C	P51 MI6.2 Throat swab gram stain A
Thurs	L12 OG1.1,2 Maternal Perinatal mortality	L76 PA29.1,2 Testicular tumors, Ca Penis			SDL7	P51 PH5.4 Drug Cost compliance B	P51 MI6.2 Throat swab gram stain C
Fri	L11 FM2.11,12, 13,14,15	L67 MI 8.4 Emerging Reemerging inf			SDL8	P53, PH5.5 OTC, Drug dependenc A	P53 Mi6.3 1.2 Sputum acid fast stain B

Sat	L79 PH1.61 Nutraceutic Dietary supplemnt	L77 PA29.3,4,5 BPH, Prostate ca, Prostatitis			SDL9	P52, PH5.5 Drug dependenc e manage C	P52 MI6.3 Sputum gram stain A
-----	--	---	--	--	------	--	---

	9-10am	10-11am	11- 1.30 Clinical posting	1.30- 2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM

Mon	ASSESSMENT						
Tues	ASSESSMENT						
Wed	ASSESSMENT						
Thurs	ASSESSMENT						
Fri	ASSESSMENT						
Sat	ASSESSMENT						

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	P2 CM 7.5 Epidemiological study Descriptive	L68 MI8.4 Bioterrorism agents			SDL10	P52, PH5.5 Drug dependence manage B	P52 MI6.3 Sputum gram stain C
Tues	L69 MI8.5 healthcare asso inf	L80 PH1.64 clinical trials			L PA25.3 Viral Hepatitis	P54, PH5.7 legal ethical aspect of prescriptn A	P54 MI5.3, 8.15,1.2 pyogenic meningitis lab diag B
Wed	L78 PA29.3,4,5 BPH, Prostate ca, Prostatitis	L81 PH1.64 GCP			L PA27.5 IHD	P53, PH5.5 OTC, Drug dependence C	P53 Mi6.3 1.2 Sputum acid fast stain A
Thurs	L13 OG21.1 population control	L79 PA30.1,6 Ca Cervix, cervicitis			L PA28.2 Kidney-syndromes	P53, PH5.5 OTC, Drug dependence B	P53 Mi6.3 1.2 Sputum acid fast stain C
Fri	L12 FM2.16,17,18,19	L70 MI8.16 Cmunicable dis NHP			L PA28.5 GN	P55, PH3.6 interaction with representative A	P55 MI7.2 inf syn genital tract B
Sat	L82 PH1.63 Legalaspect Drug regulatn	L80 PA30.7,8,9 Ca Cervix, cervicitis			L PA28.6 IgA Nephropathy	P54, PH5.7 legal ethical aspect of prescriptn C	P54 MI5.3, 8.15,1.2 pyogenic meningitis lab diag A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	P3 CM 7.5 Epidemiological Cohort Study	L13 CM 7.7 epidemic of communicable disease			L PA30.4 Ovarian tumors	P54, PH5.7 legal ethical aspect of prescriptn B	P54 MI5.3, 8.15,1.2 pyogenic meningitis lab diag C
Tues	L71 MI 8.5 inf control basics	L83 PH1.51,52 1.62 adulterant, pesticide, anti septic, poisoning			L PA30.5 GTD	P56 P1.4 ADME A	P56 MI8.11 respect pat sample B
Wed	L81 PA30.2,3 CA Endometrium, leiomyoma, leiomyosarcomas	PH1.51,51,1.62 SDL 1			L PA32.1 Iodine dependent thyroid swelling	P55, PH3.6 interaction with representative C	P55 MI7.2 inf syn genital tract A
Thurs	L14 OG27.3 Pelvic infection	L82 PA30.4,5 Ovarian tumors, GTDs			PA32.2,3 Thyrotoxicosis + hypothyroidism	P55, PH3.6 interaction with representative B	P55 MI7.2 inf syn genital tract C
Fri	AETCOM	L14, CM 3.6, 3.7 vectors in the causation of diseases, life cycles, Public Health control measure			PA32.4 Diabetes mellitus	P57 P1.4 ADME A	P57, MI8.14 patient identity confidentiality B
Sat	Holiday						

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	P4 CM 7.5 Epidemiological Study Experimental	L15 CM 14.1, 14.2 , 14.3hospital waste management			PA32.5,6 Hyperparathyroidism, pancreatic ca	P56 P1.4 ADME B	P56 MI8.11 respect pat sample C
Tues	SDL1	SDL 2			PA32.7,8,9 Adrenal insufficiency, Cushing's syndrome, Adrenal neoplasm	P58 PH1.5 Mechanism of drug action A	B
Wed	L83 PA31.1 Benign breast ds	SDL 3			SDL11	P56 P1.4 ADME C	P56 MI8.11 respect pat sample A
Thurs	L15 OG 22.1 Abnormal vaginal discharge	L84 PA31.2 Ca Breast + Gynecomasti a			SDL12	P57 P1.4 ADME B	P57,MI8.14 patient identity confidentiall ity C
Fri	L13 FM2.24	L16 CM 8.3 National Health Program			SDL13	P59 PH1.5 Mechanism of drug action A	B

Sat

Holiday

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	P5 CM 7.7 Investigation of epidemic of communicable disease	L17 CM6.4 statistical methods including test of significance in various study			SDL14	P58 P58 PH1.5 Mechanism of drug action A B	P1 FM3.1 (Corpus delicti, Identification from Race, Sex, Religion, Stature, Complexion) C
Tues	SDL2	L18 CM 8.3 National Health Programs Tuberculosis			SDL15	P60 PH4.2 CAL A	P1 FM3.1 (Corpus delicti, Identification from Race, Sex, Religion, Stature, Complexion) B
Wed	L85 PA32.1 iodine dependency of thyroid swellings	L83 PH1.44, 1.45 TB, XDR, MDR			SDL16	P57 P1.4 ADME C	P1 FM3.1 (Corpus delicti, Identification from Race, Sex, Religion, Stature, Complexion) A
Thurs	L16 OG4.4 Placenta Amniotic fluid	L86 PA32.2,3 Thyrotoxicosis + hypothyroidism			SDL17	P59 PH1.5 Mechanism of drug action B	P2 FM3.1(Skull, Mandible, Sternum) C

Fri	AETCOM	SDL3			SDL18	P61 PH4.2 CAL A	P2 FM3.1 (Skull, Mandible, Sternum) B
Sat	L36 PH1.44, 1.45 SDL 4	L87 PA32.4 Diabetes mellitus			SDL19	P58 P58 PH1.5 Mechanism of drug action A C	P2 FM3.1 (Skull, Mandible, Sternum) A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	P6 CM 7.6 need of screening test	SDL4			P60 A	P60 PH4.2 CAL B	P3 FM3.1 (Pelvis, Sacrum) C
Tues	SDL5	L19 CM 3.6, CM 8.3 NHP National Vector Borne Disease Control Programme			SDL20	P62 PH4.1Drug administratn mannequin A	P3 FM3.1 (Pelvis, Sacrum) B
Wed	L36	L37			P24 B	P24 C	P3 FM3.1 (Pelvis, Sacrum) A
Thurs	L17 OG17.1 lactation physiology	L88 PA32.5,6 Hyperparathy roidism, pancreatic ca			SDL21	P61 PH4.2 CAL B	P4 FM3.1 (Teeth) C
Fri	L14 FM2.25	SDL6			SDL22	P63 PH4.1Drug administratn mannequin A	P4 FM3.1 (Teeth) B
Sat	L84 PH1.47 malaria, kalazar, amoebiasis, helminth	L89 PA32.7,8,9 Adrenal insufficiency, Cushing's syndrome, Adrenal neoplasm			SDL23	P59 PH1.5 Mechanism of drug action C	P4 FM3.1 (Teeth) A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	P8 CM 7.8 Principles of association, causation and biases in epidemiologi cal study	L20 CM 8.3 NHP including their prevention and treatment of a case : NPCDC			SDL24	P62 PH4.1Drug administratn mannequin B	P5 FM3.1 (Radiography & Age estimation) C
Tues	SDL7	SDL5 PH1.47 malaria, kalazar			SDL25	P64 Ph2.2, ORS prepare A	P5 FM3.1 (Radiography & Age estimation) B
Wed	L90 PA33.1,2 Osteomyeli tis, Bone tumors	SDL 6			SDL26	P60 PH4.2 CAL C	P5 FM3.1 (Radiography & Age estimation) A
Thurs	L18 OG2.1 Female pelvis	L91 PA33.3,4 Soft tissue tumors, Paget's ds			SDL27	P63 PH4.1Drug administratn mannequin B	P6 FM3.2 (Hair, Dactylograph y) C
Fri	AETCOM	SDL8			SDL28	P65 PH2.3 IN drip set A	P6 FM3.2 (Hair, Dactylograph y) B

Sat	SDL 7	L92 PA33.5 Rheumatoid arthritis			SDL29	P61 PH4.2 CAL C	P6 FM3.2(Hair, Dactylograph y) A
-----	-------	--	--	--	-------	--------------------------	--

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	P9 CM 7.9 Application of computers in Epi demiology	SDL9			PA33.5 Rheumatoid arthritis	P64 Ph2.2, ORS prepare B	P7 FM3.2(Tattoo , Scars, Footprints, Superimpositi on) C
Tues	SDL10	SDL8			PA34.1 SCC	P66 PH2.4 dose calculation A	P7 FM3.2(Tattoo , Scars, Footprints, Superimpositi on) B
Wed	L36	L37			P24 B	P24 C	P7 FM3.2(Tattoo , Scars, Footprints, Superimpositi on) A
Thurs	L19 OG2.1 Anatomy reproductive organ	L93 PA34.1 SCC			PA34.2 BCC	P65 PH2.3 IN drip set B	P8 FM3.3(Abrasi on, Bruise) C
Fri	L15 FM2.25	L34			PA34. 3 Melanoma	P67 PH3.4 ADR reporting	P8 FM3.3(Abrasi on, Bruise) B
Sat	SDL9	L94 PA34.2 BCC			PA34. 3 Melanoma	P62 PH4.1Drug administratn mannequin C	P8 FM3.3(Abrasi on, Bruise) A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	P10 CM10.5 Universal Immunization Program	L6 CM7.2			SDL	P66 PH2.4dose calculation B	P9 FM3.3 (Laceration, Incised) C
Tues	L30	SDL 10			SDL	P68 PH3.2 Prescription audit A	P9 FM3.3 (Laceration, Incised) B
Wed	L95 PA34.3 Melanoma	P11 CM 3.8 Commonly used insecticides and rodenticide			SDL	P63 PH4.1Drug administratn mannequin C	P9 FM3.3 (Laceration, Incised) A
Thurs	L20 OG80.3 Placenta and fetal circulation	L96 PA35.1,2 CSF findings + CNS tumors			SDL	P67 PH3.4 ADR reporting B	P10 FM3.3 (Stab, Chop, Defense, Fabricated) C
Fri	AETCOM	L31			SDL	P69 PH3.1 prescription criticism A	P10 FM3.3 (Stab, Chop, Defense, Fabricated) B
Sat	L21 OG6.1 pregnancy diagnosis	L97 PA36.1 Retinoblastoma			SDL	P64 Ph2.2, ORS prepare C	P10 FM3.3 (Stab, Chop, Defense, Fabricated) A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L21 OG7.1 physiological changes in pregnancy	P12 CM 19.1, 19.2, 19.3 EML, counterfeit medicine and its prevention			SDL	P68 PH3.2 Prescription audit B	P11 ✓ FM2.2 0(Defi ne & Classif y Mecha nical Asphy xia) FM2.21 (Hanging) C
Tues	L33	SDL11			SDL	A	P11 ✓ FM2.2 0(Defi ne & Classif y Mecha nical Asphy xia) FM2.21 (Hanging) B
Wed	SDL	SDL12			SDL	P65 PH2.3 IN drip set C	P11 ✓ FM2.2 0(Defi ne & Classif y Mecha nical Asphy xia) FM2.21 (Hanging) A

Thurs	L22 OG7.1 physiological changes in pregnancy	SDL			SDL	P69 PH3.1 prescription criticism B	P12 ✓ FM2.2 1 (Stra ngulati on) FM2.22 (Traumatic asphyxia/ Suffocation/ Sexual asphyxia) C
Fri	L6	P13 CM8.1 laboratory tests at the primary care level for communicable disease			SDL	P27 A	P12 ✓ FM2.2 1 (Stra ngulati on) FM2.22 (Traumatic asphyxia/ Suffocation/ Sexual asphyxia) B
Sat	L23 OG 2.1 nerve , blood supply of pelvic organ	P14 CM 3.6, 3.7 life cycles of vectors of Public Health control measures			SDL	P66, P67 PH2.4dose calculation PH3.4 ADR reporting C	P12 ✓ FM2.2 1 (Stra ngulati on) FM2.22 (Traumatic asphyxia/ Suffocation/ Sexual asphyxia) A

	9-10am	10-11am	11-1.30 Clinical posting	1.30-2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM
Mon	L12	P15 CM 5.7 Food hygiene			SDL	P24 B	P13 FM2.23 (Drowning) C
Tues	L30	L24 OG3.1 fertilization			SDL	P24 A	P13 FM2.23 (Drowning) B
Wed							
Thurs							
Fri	AETCOM	P16 CM 3.3 the aetiology and basis of water borne disease			SDL	P25 A	P14 ✓ FM2.2 9 (Demo nstrate record of eviden ce in Courts by <i>Role Play</i>) FM2.30 (Knowledge about Government/ Court notifications of MLI) B

Sat	L25 OG17.1 lactation physiology	SDL			SDL	P 68,69 PH3.2 Prescription Audit criticism C	P13 FM2.23 (Drowning) A
-----	--	-----	--	--	-----	---	----------------------------------

	9-10am	10-11am	11- 1.30 Clinical posting	1.30- 2.30pm recess	Practical 2.30-4.30pm		
					Patho	Pharma	Micro/FSM

Mon	ASSESSMENT						
-----	------------	--	--	--	--	--	--

Tues	ASSESSMENT						
------	------------	--	--	--	--	--	--

Wed	ASSESSMENT						
-----	------------	--	--	--	--	--	--

Thurs	ASSESSMENT						
-------	------------	--	--	--	--	--	--

Fri	ASSESSMENT
Sat	ASSESSMENT

